Clinical Trials Logo

Resistant Cancer clinical trials

View clinical trials related to Resistant Cancer.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06347068 Not yet recruiting - Breast Cancer Clinical Trials

Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells

Start date: May 2024
Phase: Phase 1
Study type: Interventional

This phase 1, single-center, open-label study explores the safety of escalating doses of chimeric antigen receptor T cells (CAR-T) cells in subjects with relapsed/refractory triple-negative breast cancer (TNBC).

NCT ID: NCT06158139 Not yet recruiting - Pancreas Cancer Clinical Trials

Autologous CAR-T Cells Targeting B7-H3 in PDAC

Start date: June 2024
Phase: Phase 1
Study type: Interventional

The purpose of this gene therapy research study is to test the safety and tolerability of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen (iC9.CAR.B7-H3 T cells) in patients with pancreatic ductal adenocarcinoma that came back after receiving standard therapy for this cancer. The iC9.CAR.B7-H3 treatment is experimental and has not been approved by the Food and Drug Administration.

NCT ID: NCT05889312 Not yet recruiting - Cancer Clinical Trials

Assessing Cancer Treatment Response to Therapy Using 18F-FSPG PET

Start date: September 2023
Phase:
Study type: Observational

Prospective single centre non-randomised exploratory observational study to measure changes in tumour cellular redox status with 18F-FSPG PET in stage 3 non-small cell lung cancer (NSCLC) and stage 3 and 4 head and neck squamous cell cancer (HNSCC) at baseline and during standard of care treatment, and to compare this with 18F-FDG PET/CT and RECIST 1.1 response at 12 weeks.